Haemonetics Corporation (HAE) - Long-Term Liabilities to Capital

Haemonetics Corporation (HAE) develops blood purification systems, leveraging patent protection and hospital support under strict FDA oversight. This price chart on GURU.Markets with the 1.40 indicator links these advantages to environmental initiatives aimed at reducing plastic waste. Business stability is further complemented by a neutral geopolitical backdrop and reliable raw material imports, minimizing production threats within the humanitarian sector.

Developing high-margin equipment for plasma collection and surgery requires significant capital expenditures, which is reflected in the financing structure of Haemonetics Corporation (HAE). This ratio measures the proportion of long-term liabilities relative to equity, allowing for an assessment of balance sheet stability and the risks of over-leverage, as clearly illustrated by the long-term debt-to-equity history.